Larson Financial Group LLC Bellus Health Inc. Transaction History

Larson Financial Group LLC

  • $1.92 Billion
  • Q4 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 03, 2023
BUY
$8.22 - $10.76 $9,370 - $12,266
1,140 New
1,140 $9,000

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0
View Full List

About BELLUS Health Inc.

BLU Quotes by TradingView
  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email